HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2024年 / 22卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：16
相关论文
共 50 条
  • [1] HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
    Hurvitz, Sara
    Loi, Sherene
    O'Shaughnessy, Joyce
    Okines, Alicia
    Tolaney, Sara
    Sohn, Joo Hyuk
    Saura, Cristina
    Zhu, Xiaofu
    Cameron, David
    Bachelot, Thomas
    Hamilton, Erika
    Curigliano, Giuseppe
    Wolff, Antonio
    Harbeck, Nadia
    Masuda, Norikazu
    Vahdat, Linda
    Zaman, Khalil
    Valdes-Albini, Frances
    Block, Margaret
    Pluard, Timothy
    Tan, Tira
    Gawryletz, Chelsea
    Chan, Arlene
    Bedard, Philippe
    Yerushalmi, Rinat
    Xu, Binghe
    Tryfonidis, Konstantinos
    Schmitt, Michael
    Xie, Joan
    Borges, Virginia
    CANCER RESEARCH, 2024, 84 (09)
  • [2] HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+breast cancer
    Hurvitz, Sara
    Vahdat, Linda
    Harbeck, Nadia
    Wolff, Antonio C.
    Tolaney, Sara M.
    Loi, Sherene
    Masuda, Norikazu
    O'Shaughnessy, Joyce
    Dong, Cassie
    Walker, Luke
    Rustia, Evelyn
    Borges, Virginia F.
    CANCER RESEARCH, 2021, 81 (04)
  • [3] HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally advanced or metastatic HER2+breast cancer
    Hurvitz, S. A.
    Vahdat, L. T.
    Harbeck, N.
    Wolff, A. C.
    Tolaney, S. M.
    Loi, S.
    Masuda, N.
    O'Shaughnessy, J.
    Dong, C.
    Walker, L.
    Rustia, E.
    Borges, V.
    ANNALS OF ONCOLOGY, 2020, 31 : S390 - S390
  • [4] Trastuzumab emtansine in HER2-positive metastatic breast cancer
    Montemurro, Filippo
    LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697
  • [5] HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+breast cancer
    Masuda, N.
    Hurvitz, S.
    Vahdat, L.
    Harbeck, N.
    Wolff, A. C.
    Tolaney, S. M.
    Loi, S.
    O'Shaughnessy, J.
    Xie, D.
    Walker, L.
    Rustia, E.
    Borges, V. F.
    ANNALS OF ONCOLOGY, 2020, 31 : S1267 - S1268
  • [6] Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
    Murthy, R. K.
    Loi, S.
    Okines, A.
    Paplomata, E.
    Hamilton, E.
    Hurvitz, S. A.
    Lin, N. U.
    Borges, V.
    Abramson, V.
    Anders, C.
    Bedard, P. L.
    Oliveira, M.
    Jakobsen, E.
    Bachelot, T.
    Shachar, S. S.
    Mueller, V.
    Braga, S.
    Duhoux, F. P.
    Greil, R.
    Cameron, D.
    Carey, L. A.
    Curigliano, G.
    Gelmon, K.
    Hortobagyi, G.
    Krop, I.
    Loibl, S.
    Pegram, M.
    Slamon, D.
    Palanca-Wessels, M. C.
    Walker, L.
    Feng, W.
    Winer, E. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07): : 597 - 609
  • [7] Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
    Lin, Nancy U.
    Borges, Virginia
    Anders, Carey
    Murthy, Rashmi K.
    Paplomata, Elisavet
    Hamilton, Erika
    Hurvitz, Sara
    Loi, Sherene
    Okines, Alicia
    Abramson, Vandana
    Bedard, Philippe L.
    Oliveira, Mafalda
    Mueller, Volkmar
    Zelnak, Amelia
    DiGiovanna, Michael P.
    Bachelot, Thomas
    Chien, A. Jo
    O'Regan, Ruth
    Wardley, Andrew
    Conlin, Alison
    Cameron, David
    Carey, Lisa
    Curigliano, Giuseppe
    Gelmon, Karen
    Loibl, Sibylle
    Mayor, JoAl
    McGoldrick, Suzanne
    An, Xuebei
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (23) : 2610 - +
  • [8] Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
    Emens, Leisha A.
    Esteva, Francisce J.
    Beresford, Mark
    Saura, Cristina
    De Laurentiis, Michelin
    Kim, Sung-Bae
    Im, Seock-Ah
    Wang, Yifan
    Salgado, Roberto
    Mani, Aruna
    Shah, Jigna
    Lambertini, Chiara
    Liu, Haiying
    de Haas, Sanne L.
    Patre, Monika
    Loi, Sherene
    LANCET ONCOLOGY, 2020, 21 (10): : 1283 - 1295
  • [9] TRASTUZUMAB EMTANSINE FOR THE TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER
    Haddley, K.
    DRUGS OF TODAY, 2013, 49 (11) : 701 - 715
  • [10] Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial
    Jiong Wu
    Zefei Jiang
    Zhenzhen Liu
    Benlong Yang
    Hongjian Yang
    Jinhai Tang
    Kun Wang
    Yunjiang Liu
    Haibo Wang
    Peifen Fu
    Shuqun Zhang
    Qiang Liu
    Shusen Wang
    Jian Huang
    Chuan Wang
    Shu Wang
    Yongsheng Wang
    Linlin Zhen
    Xiaoyu Zhu
    Fei Wu
    Xiang Lin
    Jianjun Zou
    BMC Medicine, 20
12345